Published in Open Ophthalmol J on June 19, 2017
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ (1998) 32.73
The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol (2006) 25.47
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med (1993) 18.15
Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology (2003) 8.98
The substance causing renal hypertension. J Physiol (1940) 7.75
Primary open-angle glaucoma. Lancet (2004) 7.63
Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol (1998) 7.34
The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med (1998) 7.18
A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res (2000) 6.78
Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med (2009) 6.75
The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol (1998) 6.70
International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev (2000) 6.30
Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest (2002) 6.27
Physiology of local renin-angiotensin systems. Physiol Rev (2006) 5.77
Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol (2004) 5.44
Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology (2014) 5.42
Diabetic retinopathy. N Engl J Med (2004) 5.12
Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A (2003) 5.08
A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem (2000) 4.21
Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem (2002) 3.81
A family of mammalian Na+-dependent L-ascorbic acid transporters. Nature (1999) 3.40
Multicenter Trial of Cryotherapy for Retinopathy of Prematurity: ophthalmological outcomes at 10 years. Arch Ophthalmol (2001) 3.23
The pathophysiology and treatment of glaucoma: a review. JAMA (2014) 3.15
Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes (1997) 3.08
Renin-angiotensin system revisited. J Intern Med (2008) 3.07
A CRYSTALLINE PRESSOR SUBSTANCE (ANGIOTONIN) RESULTING FROM THE REACTION BETWEEN RENIN AND RENIN-ACTIVATOR. J Exp Med (1940) 2.98
Intraocular pressure fluctuation a risk factor for visual field progression at low intraocular pressures in the advanced glaucoma intervention study. Ophthalmology (2008) 2.92
Nocturnal arterial hypotension and its role in optic nerve head and ocular ischemic disorders. Am J Ophthalmol (1994) 2.89
Effects of RAS inhibitors on diabetic retinopathy: a systematic review and meta-analysis. Lancet Diabetes Endocrinol (2015) 2.71
Isolation and characterization of a new cellular oncogene encoding a protein with multiple potential transmembrane domains. Cell (1986) 2.65
Aldosterone in congestive heart failure. N Engl J Med (2001) 2.46
Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem (1990) 2.41
Identification of transforming growth factor-beta as an immunosuppressive factor in aqueous humor. Invest Ophthalmol Vis Sci (1991) 2.37
'What controls aqueous humour outflow resistance?'. Exp Eye Res (2006) 2.35
Intraocular pressure changes and ocular biometry during Sirsasana (headstand posture) in yoga practitioners. Ophthalmology (2006) 2.24
The trabecular meshwork outflow pathways: structural and functional aspects. Exp Eye Res (2009) 2.17
Circulating and tissue angiotensin systems. J Clin Invest (1987) 2.16
Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)-Mas axis. Exp Physiol (2008) 2.11
Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension (2003) 2.10
Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem J (2004) 1.98
Angiotensin II-forming pathways in normal and failing human hearts. Circ Res (1990) 1.97
Neovascularization produced by angiotensin II. J Lab Clin Med (1985) 1.93
Temba glaucoma study: a population-based cross-sectional survey in urban South Africa. Ophthalmology (2003) 1.85
Emerging evidence for a functional angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS receptor axis: more than regulation of blood pressure? Hypertension (2007) 1.81
The intrarenal renin-angiotensin system and diabetic nephropathy. Trends Endocrinol Metab (2003) 1.74
Effects of captopril related to increased levels of prostacyclin and angiotensin-(1-7) in essential hypertension. J Hypertens (1996) 1.73
Identification of lymphatics in the ciliary body of the human eye: a novel "uveolymphatic" outflow pathway. Exp Eye Res (2009) 1.67
Intraocular pressure variation during weight lifting. Arch Ophthalmol (2006) 1.64
Does renin-angiotensin system blockade have a role in preventing diabetic retinopathy? A clinical review. Int J Clin Pract (2011) 1.59
Angiotensin II potentiates vascular endothelial growth factor-induced angiogenic activity in retinal microcapillary endothelial cells. Circ Res (1998) 1.59
Adherence and persistence with glaucoma therapy. Surv Ophthalmol (2008) 1.57
The blood-ocular barriers. Surv Ophthalmol (1979) 1.57
Aqueous humor dynamics: a review. Open Ophthalmol J (2010) 1.55
Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma. Nat Rev Drug Discov (2012) 1.52
Update on tissue renin-angiotensin systems. J Mol Med (Berl) (2008) 1.50
Angiotensin-(1-7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects. Am J Physiol Heart Circ Physiol (2005) 1.49
Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin system. J Endocrinol (2013) 1.48
Angiotensin II and vascular inflammation. Med Sci Monit (2005) 1.44
Pathophysiology of diabetic retinopathy. ISRN Ophthalmol (2013) 1.44
Therapeutic implications of the vasoprotective axis of the renin-angiotensin system in cardiovascular diseases. Hypertension (2009) 1.41
Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders. Am J Ophthalmol (2002) 1.36
Angiotensin levels in the eye. Invest Ophthalmol Vis Sci (1994) 1.36
Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy. J Clin Endocrinol Metab (1989) 1.35
Retinal neovascularization is prevented by blockade of the renin-angiotensin system. Hypertension (2000) 1.35
Correlation between cytosolic free Ca2+ and aldosterone production in bovine adrenal glomerulosa cells. Evidence for a difference in the mode of action of angiotensin II and potassium. J Biol Chem (1984) 1.34
Retinal autoregulation in open-angle glaucoma. Ophthalmology (1984) 1.32
Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2 alpha-1-isopropylester in the cynomolgus monkey. Exp Eye Res (1989) 1.31
Comparative effectiveness of treatments for open-angle glaucoma: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med (2013) 1.31
Optic nerve blood flow is diminished in eyes of primary open-angle glaucoma suspects. Am J Ophthalmol (2001) 1.30
Angiotensin-(1-7) and the renin-angiotensin system. Curr Opin Nephrol Hypertens (2007) 1.30
The prevalence of primary angle closure glaucoma in European derived populations: a systematic review. Br J Ophthalmol (2012) 1.30
The renin-angiotensin system and diabetes: an update. Vasc Health Risk Manag (2008) 1.30
Recent developments in understanding the pathophysiology of elevated intraocular pressure. Curr Opin Ophthalmol (2006) 1.29
The effect of exercise on intraocular pressure. I. Human beings. Invest Ophthalmol (1970) 1.28
The ins and outs of aqueous humour secretion. Exp Eye Res (2004) 1.26
Uveoscleral outflow--a review. Exp Eye Res (2009) 1.25
(Pro)renin receptor-mediated signal transduction and tissue renin-angiotensin system contribute to diabetes-induced retinal inflammation. Diabetes (2009) 1.24
Effects of prostaglandins on the aqueous humor outflow pathways. Surv Ophthalmol (2002) 1.22
Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy. Br J Ophthalmol (2002) 1.21
Nitric oxide and endothelin-1 are important regulators of human ophthalmic artery. Invest Ophthalmol Vis Sci (1992) 1.19
Angiotensin-(1-7) and its effects in the kidney. ScientificWorldJournal (2009) 1.17
Statins and other cholesterol-lowering medications and the presence of glaucoma. Arch Ophthalmol (2004) 1.15
The renin-angiotensin system in retinal health and disease: Its influence on neurons, glia and the vasculature. Prog Retin Eye Res (2010) 1.15
Novel therapeutic targets for hypertension. Nat Rev Cardiol (2010) 1.13
Tissue angiotensin II generating system by angiotensin-converting enzyme and chymase. J Pharmacol Sci (2006) 1.13
ACE2: more of Ang-(1-7) or less Ang II? Curr Opin Nephrol Hypertens (2011) 1.12
Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. Am J Physiol (1997) 1.12
Renin in dog brain. Am J Physiol (1971) 1.12
Angiotensin II type 1 receptor-mediated inflammation is required for choroidal neovascularization. Arterioscler Thromb Vasc Biol (2006) 1.12
Retinal angiogenesis is mediated by an interaction between the angiotensin type 2 receptor, VEGF, and angiopoietin. Am J Pathol (2003) 1.11
Renin: origin, secretion and synthesis. J Physiol (2003) 1.10
Proceedings of the Third International Symposium on Retinopathy of Prematurity: an update on ROP from the lab to the nursery (November 2003, Anaheim, California). Mol Vis (2006) 1.10
Proteome analysis of human aqueous humor. Invest Ophthalmol Vis Sci (2010) 1.09
Aqueous humor outflow: what do we know? Where will it lead us? Invest Ophthalmol Vis Sci (2006) 1.07
Catalogue of soluble proteins in the human vitreous humor: comparison between diabetic retinopathy and macular hole. J Chromatogr B Analyt Technol Biomed Life Sci (2002) 1.07
Renin-containing Müller cells of the retina display endocrine features. Invest Ophthalmol Vis Sci (1995) 1.06
The source of proteins in the aqueous humor of the normal rabbit. Invest Ophthalmol Vis Sci (1990) 1.06
The mechanism of aqueous humour formation. Clin Exp Optom (2002) 1.06
Correlation between angiotensin-converting enzyme, vascular endothelial growth factor, and matrix metalloproteinase-9 in the vitreous of eyes with diabetic retinopathy. Am J Ophthalmol (2006) 1.05
Angiotensin(1-7) and ACE2, "The Hot Spots" of Renin-Angiotensin System, Detected in the Human Aqueous Humor. Open Ophthalmol J (2015) 0.78